Madopar® Quick (Benserazide Hydrochloride, Levodopa)

Madopar® Quick, a Levodopa/benserazide combination, is used in the management of Parkinsonian disorders by restoring dopaminergic activity in the brain.

• Parkinson's disease: improves motor symptoms such as bradykinesia, rigidity and tremor.
• Drug‑induced Parkinsonian syndrome: alleviates motor deficits caused by dopamine‑blocking agents.
• Early‑stage Parkinson’s disease: provides symptomatic relief to maintain functional independence.

• Levodopa is a precursor that crosses the blood‑brain barrier and is decarboxylated to dopamine within central neurons. Benserazide, a peripheral aromatic L‑amino acid decarboxylase inhibitor, does not cross the barrier and blocks peripheral conversion of levodopa, thereby increasing the amount of levodopa reaching the brain and enhancing dopaminergic stimulation of striatal receptors. The combined action results in more consistent central dopamine levels, reducing motor fluctuations associated with Parkinson’s disease.

Madopar® Quick may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: gastrointestinal upset occurring in many patients.
• Orthostatic hypotension: drop in blood pressure upon standing.
• Dyskinesia: involuntary movements, especially with long‑term use.
• Dry mouth: reduced salivation.
• Insomnia: difficulty initiating or maintaining sleep.
• Vomiting: expulsion of stomach contents.
• Dizziness: sensation of light‑headedness.

Serious or Rare Side Effects

• Neuroleptic malignant syndrome: life‑threatening reaction with fever and rigidity.
• Severe hypotension: marked drop in blood pressure leading to fainting.
• Cardiac arrhythmias: irregular heart rhythms.
• Psychosis: hallucinations or delusional thoughts.
• Allergic reactions: rash, pruritus, or anaphylaxis.
• Severe depression: marked mood lowering and suicidal thoughts.

When prescribing Madopar® Quick, clinicians should consider several precautionary measures to ensure safe use.

• Renal impairment: adjust therapy as reduced clearance may increase plasma levels.
• Hepatic dysfunction: monitor liver function because metabolism may be altered.
• Cardiovascular disease: use caution due to risk of orthostatic hypotension and arrhythmias.
• Psychiatric history: monitor for emergence of hallucinations or psychosis.
• Concomitant MAO‑B inhibitors: avoid or separate dosing to prevent hypertensive crisis.
• Store at ambient temperature: keep below 25 °C in the original packaging, protect from moisture and light.

Madopar® Quick can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Non‑selective MAO inhibitors: may cause hypertensive crisis.
• Antipsychotics (e.g., haloperidol): block dopamine receptors and reduce therapeutic effect.
• High‑dose pyridoxine (vitamin B6): accelerates peripheral levodopa metabolism, diminishing benefit.

Moderate Interactions (Monitor Closely)

• Antihypertensives: additive blood‑pressure lowering effect.
• SSRIs and SNRIs: may increase risk of serotonin syndrome.
• Iron or calcium supplements: reduce levodopa absorption if taken concurrently.
• Diuretics: may potentiate orthostatic hypotension.
• Carbonic anhydrase inhibitors: may enhance dopaminergic side effects.